David Roth
Industry Advisor

Dr. Roth is presently the Senior Vice President of Research and Development at CODA Genomics, Inc., in Laguna Hills, CA, a privately held biotechnology company spun out of technologies invented at, licensed from, and developed in close collaboration with scientists at UC-Irvine beginning in 2005. CODA applies its proprietary technologies using computational and synthetic biology to design and build genes for optimal protein expression and function. CODA’s business model is to drive revenues via synthetic gene programs for optimized protein production for clients and partnering to solve customers' demanding protein challenges. David is responsible for creating, developing, and executing CODA’s product and technologies pipeline, developing and managing the intellectual property portfolio, and creating business and academic alliances for grants and contracts (including the NIH and DOE), collaborations, and strategic relationships. He works closely with CODA’s Market Development, Business Development, Operations, and Sales and Marketing teams to conceive, propose and manage corporate- and USG- funded partnerships.

Prior to his work at CODA David spent 3 years as the VP-R&D at Gene Therapy Systems, Inc., a startup biotech company in San Diego specializing in molecular tools aimed at the DNA, RNA and protein delivery markets, and the development of proprietary platform technologies for antigen discovery used for vaccine and diagnostic product development. At GTS David identified new funding opportunities, spearheaded and wrote successful collaborative grant and contract applications, and worked as the business development and lead scientist to promote and raise money for the company by identifying and negotiating contracted services, strategic alliances and partnerships with vaccine and diagnostic companies, US government (including NIH and the NMRC) and international agencies, and non-profit organizations. He designed and oversaw the development of new catalog-driven products and wrote new patent applications for novel products invented in-house. David also created and directed collaborations between GTS and biotechnology, pharmaceutical, vaccine and diagnostics partners (strategic alliances, joint ventures, grant- and contract-based collaborations and partnerships), academic and institutional collaborations, and scientific consultants.

David began his industry career at Collateral Therapeutics, Inc. in San Diego, where he was the Director of Research and Technology for over 4.5 years where he planned and managed R&D projects in these integrated fields: cell and molecular biology, biochemistry, rodent physiology (rats, mice, transgenics), large animal physiology and pharmacology (pigs, rabbits), and process development. David directed and coordinated internal interactions between these departments: research program planning and management, quality assurance, regulatory affairs (including FDA interactions), legal/in-house counsel (patents, licensing, intellectual property), process development and manufacturing (GLP, GMP, QC), pre-clinical and clinical development, product development, human resources, financial planning and budgets. He also provided leadership during evaluation and prioritization of programs and projects during acquisition/transition phases of Collateral Therapeutics with Schering AG-Germany, and it’s wholly owned US subsidiary, Berlex Biosciences.

Prior to working in the biotech industry, David was an Assistant Professor and Director of the Molecular Physiology Laboratory in the Department of Integrative Physiology at the University of Colorado in Boulder. Along with running successful research programs, he was also the recipient of the University’s Teaching Excellence Award given by the Student Organization for Alumni Relations (SOAR) for tenure track faculty for the 30-75 undergraduate student class size. 

David received his BS, MS and PhD degrees at UC-Berkeley in the laboratory of Prof. George Brooks, PhD, and completed a postdoctoral fellowship at UC-San Diego School of Medicine with Prof. H. Kirk Hammond, MD, in Molecular Cardiology.

Team
Board Members
Investment Committee
Global Advisory Council

contact us | terms of use | site map | privacy policy | jobs